Contact Info

Introducing Leksell Gamma Knife® 4C for Treatment Solutions in the Brain

Leksell Gamma Knife® 4C: the most successful radiosurgery weapon in the fight against brain disorders

Leksell Gamma Knife® 4C* is the fourth generation of the most successful radiosurgery weapon in the fight against brain disorders, with enhancements designed to improve workflow, increase accuracy and provide integrated imaging capabilities. The integrated imaging, powered by Leksell Gamma PlanŽ, offers users an unprecedented ability to integrate images from multiple sources to achieve the most accurate treatment capability ever. These images can also be exported on a CD-ROM, so the referring physician can receive pre-op or post-op images for reference and follow-up.

The new features and advancements on Leksell Gamma KnifeŽ 4C are both visually appealing and increase functionality. Operators now have the flexibility to view planning information on both sides of the couch, and the redesigned operator console is more intuitive and easier to use. The faster, more efficient helmet changer and robotic Automatic Positioning SystemŽ streamline operations and reduce treatment time.

*Leksell Gamma Knife® 4C and Leksell GammaPlan® 4C are works in progress and are not yet available for sales or distribution in the U.S.

Setting the Standard in Radiosurgery

Leksell Gamma KnifeŽ remains the most proven means of performing intracranial stereotactic radiosurgery, and is the single most trusted and utilized solution for treating brain disorders without invasive surgery. Over 250,000 patients have been treated using Gamma KnifeŽ surgery and there are 2,000 peer-reviewed published papers. Patients and physicians prefer the convenience and efficacy of a single dose achieved with clinical confidence using Leksell Gamma KnifeŽ.

Leksell Gamma KnifeŽ is part of a complete and successful practice, offering a proven business model that reduces risk while allowing centers to reach profitability faster. Leksell Gamma KnifeŽ is installed in 200 clinics worldwide, and all original sites are still operating. With increasing patient volumes and a growing number of indications treatable using Gamma KnifeŽ surgery, centers are finding their investment in Leksell Gamma KnifeŽ to be sound. They also benefit from being perceived as a leader both in technology and thought leadership, as well as additional income from performing associated procedures.

Gamma KnifeŽ surgery is used for a variety of neurological disorders, including AVMs, vestibular schwannomas, meningiomas, pituitary tumors, trigeminal nerve targets and brain metastases. Research is being conducted on other possible uses of Leksell Gamma KnifeŽ, such as treating epilepsy, Parkinson's disease and uveal melanoma.

Fighting Serious Disease

The strength of Elekta's diverse and specialized treatment solutions provides a solid market position, which is being strengthened with the introduction of leading edge, emerging clinical applications of technology. With a robust pipeline of new orders for Leksell Gamma KnifeŽ and Elekta Synergy™, Elekta has proven that it is a company that will continue to make a difference in the lives of patients today and in the years to come.

Elekta is a world-leading supplier of advanced and innovative radiation oncology and neurosurgery solutions and services for precise treatment of cancer and brain disorders. Elekta's solutions are clinically effective, cost efficient and gentle to the patient. The company's North American headquarters are located in Atlanta and corporate headquarters are in Stockholm, Sweden. For additional information about Elekta, please visit www.elekta.com